332 related articles for article (PubMed ID: 15262305)
21. Monitoring the decrease of circulating malignant T cells in cutaneous T-cell lymphoma during photopheresis and interferon therapy.
Ferenczi K; Yawalkar N; Jones D; Kupper TS
Arch Dermatol; 2003 Jul; 139(7):909-13. PubMed ID: 12873887
[TBL] [Abstract][Full Text] [Related]
22. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series.
Singh F; Lebwohl MG
J Am Acad Dermatol; 2004 Oct; 51(4):570-3. PubMed ID: 15389192
[TBL] [Abstract][Full Text] [Related]
23. [Current therapy concepts in cutaneous T-cell lymphomas].
Nestle FO; Häffner AC; Schmid MH; Dummer R; Burg G
Schweiz Med Wochenschr; 1997 Feb; 127(8):311-20. PubMed ID: 9157537
[TBL] [Abstract][Full Text] [Related]
24. Plaque stage mycosis fungoides treated with bexarotene at low dosage and UVB-NB.
D'Acunto C; Gurioli C; Neri I
J Dermatolog Treat; 2010 Jan; 21(1):45-8. PubMed ID: 19603308
[TBL] [Abstract][Full Text] [Related]
25. The role of maintenance phototherapy in cutaneous T-cell lymphoma.
Pothiawala SZ; Baldwin BT; Cherpelis BS; Glass LF; Fenske NA
J Drugs Dermatol; 2010 Jul; 9(7):800-3. PubMed ID: 20677536
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Kannangara AP; Levitan D; Fleischer AB
J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
[TBL] [Abstract][Full Text] [Related]
27. Combination treatment modalities in cutaneous T-cell lymphoma (CTCL).
Guitart J
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S17-20. PubMed ID: 16516671
[TBL] [Abstract][Full Text] [Related]
28. Durable complete remission of therapy-refractory, tumor-stage cutaneous T-cell lymphoma under radioimmunotherapy with electron beam irradiation and denileukin diftitox.
Wobser M; Göppner D; Lang SC; Beckmann G; Flentje M; Ugurel S; Bröcker EB; Becker JC
Arch Dermatol; 2010 Jul; 146(7):805-6. PubMed ID: 20644054
[No Abstract] [Full Text] [Related]
29. ECP versus PUVA for the treatment of cutaneous T-cell lymphoma.
Geskin L
Skin Therapy Lett; 2007 Jun; 12(5):1-4. PubMed ID: 17609808
[TBL] [Abstract][Full Text] [Related]
30. Cutaneous T-cell lymphomas: a review with emphasis on new treatment approaches.
Querfeld C; Rosen ST; Kuzel TM; Guitart J
Semin Cutan Med Surg; 2003 Sep; 22(3):150-61. PubMed ID: 14649582
[TBL] [Abstract][Full Text] [Related]
31. Future perspectives in the treatment of cutaneous T-cell lymphoma (CTCL).
Dummer R
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S33-6. PubMed ID: 16516674
[TBL] [Abstract][Full Text] [Related]
32. Skin directed therapy for mycosis fungoides: a review.
Berthelot C; Rivera A; Duvic M
J Drugs Dermatol; 2008 Jul; 7(7):655-66. PubMed ID: 18664158
[TBL] [Abstract][Full Text] [Related]
33. Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous T-cell lymphoma.
Shapiro M; Rook AH; Lehrer MS; Junkins-Hopkins JM; French LE; Vittorio CC
J Am Acad Dermatol; 2002 Dec; 47(6):956-61. PubMed ID: 12451388
[No Abstract] [Full Text] [Related]
34. Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma.
Ramsay DL; Lish KM; Yalowitz CB; Soter NA
Arch Dermatol; 1992 Jul; 128(7):931-3. PubMed ID: 1626959
[TBL] [Abstract][Full Text] [Related]
35. Cutaneous T-cell lymphoma: overview and nursing perspectives.
McCann SA
Nurs Clin North Am; 2007 Sep; 42(3):421-55, vi-vii. PubMed ID: 17825663
[TBL] [Abstract][Full Text] [Related]
36. A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis.
Rook AH; Wood GS; Duvic M; Vonderheid EC; Tobia A; Cabana B
J Am Acad Dermatol; 2010 Dec; 63(6):984-90. PubMed ID: 20889234
[TBL] [Abstract][Full Text] [Related]
37. Management of cutaneous T-Cell lymphoma patients with extracorporeal photopheresis. The Hellenic experience.
Siakantaris MP; Tsirigotis P; Stavroyianni N; Argyropoulos KV; Girkas K; Pappa V; Chondropoulos S; Papadavid E; Sakellari I; Anagnostopoulos A; Antoniou C; Dervenoulas J
Transfus Apher Sci; 2012 Apr; 46(2):189-93. PubMed ID: 22178592
[TBL] [Abstract][Full Text] [Related]
38. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies.
Duvic M
Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):33-40. PubMed ID: 17474358
[TBL] [Abstract][Full Text] [Related]
39. Management of the primary cutaneous lymphomas.
Prince HM; McCormack C; Ryan G; O'Keefe R; Seymour JF; Baker C
Australas J Dermatol; 2003 Nov; 44(4):227-40; quiz 241-2. PubMed ID: 14616487
[TBL] [Abstract][Full Text] [Related]
40. [Triple secondary malignancy of gingiva, palate and esophagus after an allogeneic bone marrow transplantation for cutaneous T-cell lymphoma].
Koharazawa H; Yamaji S; Takasaki H; Takabayashi M; Fujimaki K; Taguchi J; Kanamori H; Ishigatsubo Y
Rinsho Ketsueki; 2005 Jul; 46(7):496-500. PubMed ID: 16440741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
